Kuano: A novel second generation quantum computing technique using transition state modelling for efficient drug discovery

夸诺是一家致力于将药物发现的最新创新和技术引入制药业的公司。Kuano的独特方法解决了人工智能驱动的药物设计和目标驱动的药物发现中的共同挑战。这项可行性研究旨在利用第二代量子技术来解决药物发现部门中目前与分子模拟相关的棘手问题。Kuano将评估第二代量子技术的可行性，以克服目前与准确模拟催化过程行为相关的限制：具体地说，提取过渡态的描述并了解金属蛋白的结合机制。这将使大规模、精确的分子模拟成为可能，并支持在药物发现中的人工智能领域(以及其他工业应用)的广泛应用。项目成果是一个发现平台，旨在解锁中到高水平的纠缠，为Kuano和英国药物开发行业创造一个跨越式的变化。

Kuano is a company dedicated to bringing the latest innovation and technology for drug discovery to the pharmaceutical industry. Kuano's unique approach tackles common challenges in both AI-driven drug design and target driven drug discovery.This Feasibility Study seeks to exploit second generation quantum techniques to solve currently intractable problems associated with molecular simulation within the drug discovery sector.Kuano will evaluate the feasibility of a second-generation quantum technology to overcome current limitations associated with accurately modeling the behaviour of the catalysis process: specifically, extracting a description of the transition state and understanding the binding mechanisms for metalloproteins. This would enable large-scale, precise molecular simulations and support broad application in the field of 'AI in drug discovery' (as well as other industrial applications).The project output is a discovery platform that aims to unlock intermediate-to-high levels of entanglement, creating a step-change for Kuano and the UK drug development industry.